Division of Gastroenterology & Hepatology, Virginia Commonwealth University, Richmond, VA, USA; Division of Gastroenterology & Hepatology, Mayo Clinic, Scottsdale, AZ, USA; Division of Gastroenterology & Hepatology, Hunter Holmes McGuire VA Medical Center, Richmond, VA, USA.
Division of Gastroenterology & Hepatology, Virginia Commonwealth University, Richmond, VA, USA; Division of Gastroenterology & Hepatology, Hunter Holmes McGuire VA Medical Center, Richmond, VA, USA.
Dig Liver Dis. 2018 Nov;50(11):1220-1224. doi: 10.1016/j.dld.2018.05.014. Epub 2018 May 28.
Current practice guidelines recommend prophylactic antibiotics prior to endoscopic retrograde cholangiopancreatography (ERCP) in liver transplant recipients (LTR). This study evaluated the risk of clinically significant infections after ERCP in LTR who received antibiotic prophylaxis compared to those who did not.
This retrospective case-cohort study evaluated all LTR who underwent elective, outpatient ERCP from 2008 to 2015. Hospitalized patients, pediatric allograft recipients and patients with cholangitis or incomplete biliary drainage were excluded. The primary outcome was unanticipated hospitalization from procedure-related clinically significant infection occurring within 3 days of ERCP.
Sixty-nine patients (48 males; mean age 60.5 ± 7.4 years) underwent 191 ERCPs after liver transplantation. Prophylactic antibiotics were administered during 82 ERCPs and not administered for 109 ERCPs. Unscheduled admissions for fever within 3 days occurred in 4 patients. Only 2 patients had documented bacteremia, of which only 1 patient received prophylactic antibiotics and also met primary outcome. Interventions during ERCP, patient demographics, and time from transplantation were not associated with increased risk of hospitalization from infections or bacteremia.
The risk of infectious complications after ERCP in LTR is low and not affected by administration of prophylactic antibiotics. A tailored approach to antibiotic prophylaxis may be more appropriate than universal prophylaxis in selected LTR at low risk of infections.
目前的实践指南建议肝移植受者(LTR)在接受内镜逆行胰胆管造影(ERCP)前进行预防性抗生素治疗。本研究评估了接受抗生素预防的 LTR 与未接受抗生素预防的 LTR 在 ERCP 后发生临床显著感染的风险。
本回顾性病例对照研究评估了 2008 年至 2015 年间所有接受择期门诊 ERCP 的 LTR。排除住院患者、儿科同种异体移植物受者以及患有胆管炎或不完全胆道引流的患者。主要结局是 ERCP 后 3 天内发生的与操作相关的临床显著感染导致的意外住院。
69 例(48 例男性;平均年龄 60.5±7.4 岁)在肝移植后接受了 191 次 ERCP。82 次 ERCP 中给予了预防性抗生素,109 次 ERCP 中未给予。4 例患者在 3 天内出现发热的计划外住院。仅 2 例患者有菌血症记录,其中仅 1 例患者接受了预防性抗生素治疗,也符合主要结局。ERCP 期间的干预措施、患者人口统计学特征和移植后时间与感染或菌血症导致的住院风险增加无关。
LTR 接受 ERCP 后的感染并发症风险较低,且不受预防性抗生素使用的影响。在感染风险低的选定 LTR 中,采用有针对性的抗生素预防方法可能比普遍预防更合适。